N-[5-[[(1,2,3,4-tetrahydro-1-naphthalenyl)amino]sulfonyl]-1-naphthalenyl]acetamide | 491580-01-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-[5-[[(1,2,3,4-tetrahydro-1-naphthalenyl)amino]sulfonyl]-1-naphthalenyl]acetamide
• 英文别名: N-[5-(1,2,3,4-tetrahydronaphthalen-1-ylsulfamoyl)naphthalen-1-yl]acetamide
• CAS: 491580-01-9
• 化学式: C₂₂H₂₂N₂O₃S
• 分子量: 394.494
• InChiKey: JTGKKKAPUFQNPO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  83.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• 17 Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
  申请人：SCHERING CORPORATION

  公开号：US20040138226A1

  公开（公告）日：2004-07-15

  In its many embodiments, the present invention provides a novel class of compounds as inhibitors of type 3 17&bgr;-hydroxysteroid dehydrogenase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with type 3 17&bgr;-hydroxysteroid dehydrogenase using such compounds or pharmaceutical compositions.

  在其多种实施方式中，本发明提供了一类新型化合物，作为第3型17β-羟基类固醇脱氢酶的抑制剂，以及制备这种化合物的方法，含有一种或多种这种化合物的药物组合物，制备含有一种或多种这种化合物的药物制剂的方法，以及使用这种化合物或药物组合物进行治疗、预防、抑制或改善与第3型17β-羟基类固醇脱氢酶相关的一种或多种疾病的方法。
• [EN] 17 BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES<br/>[FR] INHIBITEURS DE 17 BETA-HYDROXYSTEROIDE DESHYDROGENASE DE TYPE 3 POUR LE TRAITEMENT DE MALADIES ANDROGENO-DEPENDANTES
  申请人：SCHERING CORP

  公开号：WO2004060488A1

  公开（公告）日：2004-07-22

  The present invention provides a novel class of compounds of formula (I): as inhibitors of type 3 17β-hydroxysteroid dehydrogenase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with type 3 17β-hydroxysteroid dehydrogenase using such compounds or pharmaceutical compositions.

  本发明提供了一种新的化合物类别，其化学式为(I)，作为3型17β-羟基类固醇脱氢酶的抑制剂，制备这种化合物的方法，含有一种或多种这种化合物的药物组合物，制备包含一种或多种这种化合物的药物制剂的方法，以及使用这种化合物或药物组合物治疗、预防、抑制或改善与3型17β-羟基类固醇脱氢酶相关的一种或多种疾病的方法。
• Sulfonamide derivatives
  申请人：——

  公开号：US20040234622A1

  公开（公告）日：2004-11-25

  A medicament for enhancing an effect of a cancer therapy based on a mode of action of DNA injury, which comprises as an active ingredient a compound represented by the general formula (I) or a physiologically acceptable salt thereof: 1 wherein R represents an aryl-substituted alkyl group, an heteroaryl-substituted alkyl group, a cycloalkyl-substituted alkyl group, or a cyclic hydrocarbon group wherein said cyclic hydrocarbon group may be saturated, partly saturated, or aromatic; or Z may bind to R to form a cyclic structure, Z represents a hydrogen atom or a C 1 to C 6 alkyl group. The medicament enhanced the effect of the cancer therapy and decreases a dose of an anticancer agent and/or radiation, and therefore, can reduce side effects resulting from the cancer therapy.

  一种用于增强基于DNA损伤作用的癌症治疗效果的药物，其包含以一般式（I）表示的化合物或其生理上可接受的盐作为活性成分： 1 其中R代表芳基取代的烷基，杂环芳基取代的烷基，环烷基取代的烷基或环烃基，其中所述环烃基可以是饱和的、部分饱和的或芳香的；或Z可以与R结合形成一个环状结构，Z代表氢原子或C1到C6烷基。该药物增强了癌症治疗的效果，并减少了抗癌剂和/或放疗的剂量，因此可以减少由癌症治疗引起的副作用。
• 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
  申请人：Guzi J. Timothy

  公开号：US20060142338A1

  公开（公告）日：2006-06-29

  In its many embodiments, the present invention provides a novel class of compounds as inhibitors of type 3 17β-hydroxysteroid dehydrogenase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with type 3 17β-hydroxysteroid dehydrogenase using such compounds or pharmaceutical compositions.

  在许多实施方案中，本发明提供了作为 3 型 17β- 羟类固醇脱氢酶抑制剂的一类新型化合物、制备此类化合物的方法、含有一种或多种此类化合物的药物组合物、制备包含一种或多种此类化合物的药物制剂的方法，以及使用此类化合物或药物组合物治疗、预防、抑制或改善与 3 型 17β- 羟类固醇脱氢酶相关的一种或多种疾病的方法。
• SULFONAMIDE DERIVATIVES
  申请人：Institute of Medicinal Molecular Design, Inc.

  公开号：EP1402890B1

  公开（公告）日：2008-01-09